Ironwood Pharmaceuticals, Inc.
IRWD
$3.73
$0.236.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.42% | -22.98% | -23.18% | -20.63% | -12.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.42% | -22.98% | -23.18% | -20.63% | -12.48% |
| Cost of Revenue | -119.44% | -92.75% | -52.03% | 22.84% | -64.71% |
| Gross Profit | -2.12% | -17.39% | -21.79% | -21.24% | -1.37% |
| SG&A Expenses | -38.75% | -28.02% | -11.83% | 1.59% | 27.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.03% | -23.19% | -8.37% | 3.60% | 42.03% |
| Operating Income | 50.76% | -22.47% | -49.96% | -51.15% | -59.09% |
| Income Before Tax | 30.74% | -50.17% | 102.38% | 106.88% | 107.90% |
| Income Tax Expenses | -12.95% | -35.65% | -22.29% | -22.96% | -0.13% |
| Earnings from Continuing Operations | 1,014.74% | -209.77% | 97.01% | 100.09% | 99.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -97.70% |
| Net Income | 1,259.11% | -185.59% | 96.93% | 100.09% | 99.74% |
| EBIT | 50.76% | -22.47% | -49.96% | -51.15% | -59.09% |
| EBITDA | 49.56% | -22.17% | -49.24% | -50.52% | -58.46% |
| EPS Basic | 1,193.13% | -183.03% | 97.04% | 100.08% | 99.74% |
| Normalized Basic EPS | 62.24% | -36.38% | -75.64% | -72.49% | -76.57% |
| EPS Diluted | 629.18% | -252.13% | 96.93% | 99.91% | 99.55% |
| Normalized Diluted EPS | 49.08% | -34.80% | -74.67% | -70.22% | -73.76% |
| Average Basic Shares Outstanding | 1.89% | 2.11% | 2.27% | 2.28% | 2.16% |
| Average Diluted Shares Outstanding | 6.65% | -0.32% | -2.49% | -7.09% | -11.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |